A new drug to combat a certain type of lung cancer is being hailed today as an "amazing development" by medical experts.
The drug crizotinib (Xalkori), manufactured by Pfizer and approved last week by the Food and Drug Administration, is intended for a small number of patients.
The twice-daily capsules are meant for patients with non-small cell lung cancer who have a unique gene known as an abnormal anaplastic lymphoma kinase(ALK). An ALK gene causes cancer growth and development.
Read more
No comments:
Post a Comment